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The poor membrane permeability of oligonucleotides is one of the major problems of antisense technology.
Here we report the construction of designer oligonucleotides for targeted delivery to macrophages. The
oligonucleotides tethered to a 10-mer poly(G) sequence at their 3* ends were recognized by scavenger receptors
on macrophages and were taken up about 8- to 10-fold as efficiently as those oligonucleotides that either lacked
a poly(G) tail or that contained a 10-mer poly(C) tail instead of the poly(G) tail. The enhanced uptake of
poly(G) constructs was inhibited in the presence of poly(G) and other known ligands of the scavenger receptor.
The bioefficacy of poly(G)-mediated targeting of antisense oligonucleotides (ANS) was demonstrated by using
vesicular stomatitis virus (VSV) as a model system. The ability of ANS directed against the translation
initiation site of N protein mRNA of VSV to inhibit virus replication was assessed. The ANS with the 10-mer
poly(G) sequences (ANS-G) brought about significant inhibition of VSV replication in J774E cells (a murine
monocyte/macrophage cell line) and Chinese hamster ovary (CHO) cell transfectants expressing scavenger
receptors. The ANS lacking a 10-mer poly(G) stretch were ineffective. The inhibition of VSV replication due to
ANS-G was completely abrogated in the presence of 10-mer poly(G), indicating that the antisense effect of the
ANS-G molecule was a consequence of scavenger receptor-mediated enhanced uptake. Importantly, antisense
molecules linked exclusively by natural phosphodiester bonds were as bioeffective as those synthesized with a
mixed backbone of phosphodiester and phosphorothioate. Taken together, these results suggest that macroph-
age-directed designer ANS against infective agents may simply be obtained by adding a short stretch of
guanylic acid sequence to the desired specific ANS during solid-phase synthesis. This nucleic acid-based
strategy, which utilizes homogeneous preparation of ANS, may find applications in directed manipulation of
macrophage metabolism for a variety of purposes as well as in therapy of a broad spectrum of macrophage-
related disorders amenable to the antisense approach.
The conceptual simplicity of antisense design, its high the-
oretical specificity, the affinity of the antisense oligonucleotides
for their targets, the ease of chemical synthesis, and the low
systemic toxicity have endowed the antisense approach with
considerable therapeutic potential, especially in the treatment
of diseases such as cancers and viral infections (44). Antisense
oligonucleotides are particularly attractive as antiviral agents
as they can be designed to block viral replication within in-
fected cells without affecting the metabolism of the host cells
(2). However, prominent among the problems that limit the
success of the antisense approach are (i) nuclease sensitivity of
the oligonucleotide molecules and (ii) inefficient uptake by
cells. While the problem of nuclease sensitivity of normal phos-
phodiester (PO) oligonucleotides has been circumvented to
some extent by modifying the phosphate backbone of the oli-
gonucleotides, as for analogs such as phosphorothioate (PS)
and methylphosphonate oligonucleotides, the poor cellular up-
take of these molecules remains a severe limitation (17).
The PO and PS oligonucleotides cannot passively diffuse
across the cell membrane because of their polyanionic nature.
Thus the processes of absorptive endocytosis and fluid phase
endocytosis appear to be the principal routes of entry of these
molecules into the cells (28, 48). However, there are reports
suggesting the presence of cell surface receptors for oligonu-
cleotides (5, 6, 21, 24, 39, 51). The putative cell membrane
proteins vary in molecular size, exhibit moderate affinities, and
bind to oligonucleotides in a specific as well as nonspecific
fashion. These unrelated proteins have not been characterized
fully, and hence their structural and functional significance is
not readily apparent. At any rate the oligonucleotide delivery
to cells remains a persistent problem considering that only 1 to
2% of the oligonucleotides become cell associated when added
directly to cells in culture (40).
Current approaches to overcome the problem of poor cel-
lular uptake of oligonucleotides include microinjection of oli-
gonucleotides (41), delivery by the calcium phosphate precip-
itation method (47), and the use of cationic lipids such as
N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-tetramethylammonium
methyl sulfate and cytofectin (27). Lipid-oligonucleotide con-
jugates (42) and cholesteryl-oligonucleotide conjugates (26),
antisense molecules conjugated either to fusogenic peptides
(9) or poly(L-lysine) (25), have been shown to be bioeffective at
concentrations at which the free oligonucleotides are ineffec-
tive. Liposome-mediated delivery (52) and receptor-mediated
delivery of antisense oligonucleotides to cells have also been
reported (14, 15, 49, 50).
Targeting of antisense oligonucleotides by using endocytic
receptor systems specific to a given cell type is an attractive
strategy for circumventing the intrinsic problems of nonper-
meability and nonspecific cellular uptake of oligonucleotides.
This strategy has been employed for delivery of antisense oli-
gonucleotides with the asialoglycoprotein receptor (50), trans-
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ferrin receptor (49), and epidermal growth factor receptor
(15). In most of these cases, the oligonucleotide molecules are
complexed to a poly(L-lysine)–ligand conjugate for delivery to
cells expressing the particular receptor. The poly(L-lysine) is
conjugated to the carrier molecule through a heterobifunc-
tional cross-linker, and the conjugate is incubated with the
oligonucleotide to allow for noncovalent association of the
oligonucleotide with the poly(L-lysine). The resultant coacer-
vates of receptor-recognizable macromolecules consist of
chemically heterogeneous complex mixtures which cannot be
easily formulated into pharmaceutical preparations for thera-
peutic applications. Thus antisense delivery strategies involving
direct chemical manipulation of oligonucleotides and yielding
a homogeneous product should be preferred over those that
generate mixtures of covalently and/or noncovalently associ-
ated molecules (17).
In this study we report a simple strategy for designing anti-
sense oligonucleotides for macrophage targeting. We show
that the presence of a short poly(G) tail at the 39 end of the
antisense sequence is sufficient for scavenger receptor (SCR)-
mediated targeting of oligonucleotides to macrophages. In a
model system, we demonstrate the enhanced cellular uptake
and bioefficacy of a vesicular stomatitis virus (VSV)-specific
antisense oligonucleotide in VSV-infected J774E cells and
CHO transfectants expressing SCR.
MATERIALS AND METHODS
Cell lines and virus. J774E, a murine monocyte/macrophage cell line, was a
gift from P. Stahl, Washington University, St. Louis, Mo. The Chinese hamster
ovary (CHO) transfectant PJA28.C5 expressing the type I SCR and the parent
CHO cell line were obtained from M. Krieger, Massachusetts Institute of Tech-
nology. All cell lines were cultured in medium A (RPMI 1640 containing 10%
fetal bovine serum [FBS] and gentamicin [50 mg/liter]) at 37°C in a 5% CO2–
95% air atmosphere. The transfectant was cultured in medium containing Ge-
neticin (400 mg/ml) as a selection marker. VSV (Indiana strain) was a kind gift
from Ranjit Ray (St. Louis University, St. Louis, Mo.). VSV was grown to high
titers in J774E cells cultured in medium B (RPMI containing 2% FBS and 50 mg
of gentamicin/ml).
Oligonucleotides. PS and chimeric antisense oligodeoxyribonucleotides were
purchased from Biosynthesis Inc., Louisville, Tex. The PO oligonucleotides were
purchased from Rama Biotechnologies, New Delhi, India. The oligonucleotide
samples were radiolabeled, and their purity was determined by polyacrylamide
gel electrophoresis. The commercially procured oligonucleotides were purified
by ion exchange chromatography using standard procedures.
CD spectroscopy. Circular dichroism (CD) spectra were recorded on a Jasco-
J710 instrument equipped with a Peltier-type constant-temperature cell holder
(PTC-348W). The instrument was calibrated with (1)-10-camphorsulfonic acid.
The spectra of oligonucleotides were recorded at 37°C, and data were presented
as mean residue ellipticity expressed in units of degrees times centimeters
squared divided by decimoles. The spectra were smoothed with the built-in
algorithm of the Jasco program.
Radiolabeling. Oligonucleotides were end labeled with a T4 polynucleotide
kinase kit (Promega, Madison, Wis.). The kination reaction was carried out on 10
pmol of the oligonucleotide at 37°C for 1 h in a total volume of 10 ml containing
10 U of the enzyme, 1 ml of 103 polynucleotide kinase buffer, and 30 mCi of
[g-32P]ATP. The labeled oligonucleotides were purified on a DE52 cellulose
matrix, and specific activity was determined.
Maleylated bovine serum albumin (MBSA) was prepared as described previ-
ously (13) and radiolabeled by a modification of the iodine monochloride
method (19). Briefly, about 2 mg of protein was added to 250 ml of 10 mM
phosphate buffer containing 150 mM NaCl (PBS; pH 7.4), 250 ml of 1 M
glycine-NaOH buffer (pH 10) was added, and the mixture was placed on ice. To
this, 1 mCi of Na125I was added, along with 125 ml of freshly made iodine
monochloride (2.64 mM) solution. The reaction mixture was vortexed and incu-
bated on ice for 10 min. The iodinated protein (125I-MBSA) was separated from
the free iodine by gel filtration with a G-25 prepacked column (10 by 1.25 cm)
equilibrated with PBS. The radiolabeled protein was extensively dialyzed at 4°C
against PBS.
Binding assays. Cells (0.5 3 106 cells/well) were plated in six-well culture
dishes in medium A and incubated for 18 h at 37°C in a humidified 5% CO2–95%
air atmosphere. The growth medium was replaced with 1 ml of ice-cold medium
C (RPMI 1640 containing BSA [1 mg/ml]) containing various concentrations of
125I-MBSA, and the cells were incubated at 4°C for 2 h. The cells were then
washed three times with ice-cold PBS containing BSA (5 mg/ml), followed by
three washes with ice-cold PBS to remove unbound radioactivity. The cells were
then lysed in 0.1 N NaOH (1 ml per well), and cell-associated radioactivity was
determined with a gamma counter.
Degradation assays. The assays were carried out as described previously (19).
Briefly, cells were plated as described above. Each well received 1 ml of pre-
warmed medium C containing 125I-MBSA alone or with putative competitors,
and the cells were incubated at 37°C for 5 h. The supernatant (500 ml) from each
well was collected, 200 ml of 50% trichloroacetic acid (TCA) was added, and the
solutions were placed at 4°C overnight. The supernatants were spun at 1,000 3
g for 10 min to pellet out the precipitated protein. To 400 ml of the TCA-soluble
supernatant, 7 ml of 40% KI and 15 ml of 30% H2O2 were added, and the mixture
was vortexed and kept at room temperature for 10 min. To each sample, 1 ml of
chloroform was added, and the samples were vortexed and kept at room tem-
perature for 10 min to allow for extraction of free iodine. The 125I content in the
aqueous phase was determined with a gamma counter. The TCA-soluble radio-
activity obtained from the “no cell blank” was subtracted from the experimental
readings to calculate cell-specific degradation, the results being expressed as
nanograms of 125I-MBSA degraded per milligram of cell protein.
Uptake assays. Cells were plated as described above. Each well received 1 ml
of medium C containing [g-32P]ATP-labeled oligonucleotide alone or with pu-
tative competitors, and the cells were incubated for different periods of time.
After this, the cells were processed as described for binding assays and cell-
associated radioactivity was determined.
Virus replication inhibition assay. Cells (0.125 3 106 cells/well) were plated in
a 24-well culture plate and were incubated at 37°C for 6 to 8 h. The cells were
washed in serum-free RPMI 1640 and incubated with the desired concentration
of oligonucleotide in 250 ml of serum-free RPMI 1640 at 37°C for 4 h. The
oligonucleotide-containing medium was then removed, and the cells were in-
fected with VSV at a multiplicity of infection (MOI) of 0.5 for 30 min in 300 ml
of serum-free RPMI 1640. The cells were then washed three times with serum-
free RPMI 1640, and the oligonucleotide-containing medium was readded along
with 50 ml of 10% FBS. The cells were now incubated at 37°C for 10 h. The cell
supernatants were collected, and viral titers were determined by plaque assays.
The assays were carried out on CHO cell monolayers by the agar overlay method.
Plates were flushed with 0.07% neutral red solution to help count the plaques,
and viral titers were calculated.
RESULTS
Design of oligonucleotides for targeted delivery to macro-
phages. VSV, which infects a variety of cell types including
macrophages, was chosen as a candidate virus for the study.
The translation initiation region of the mRNA corresponding
to the N protein of VSV was selected as a target sequence since
the antisense oligonucleotide sequence (59CATTTTGATTAC
TGT39) directed against this site has been earlier shown to
inhibit viral replication by an antisense-specific mechanism in
VSV-infected L929 cells (25).
The SCR on macrophages recognize a wide variety of poly-
anionic macromolecules including maleylated and acetylated
proteins, sulfated polysaccharides such as fucoidan, lipopoly-
saccharides, and certain polynucleotides such as poly(G) and
poly(I) (11, 18). Short stretches (6- to 10-mer) of poly(G) or
poly(I) were also shown to be effective ligands of the receptor
(11, 36). The acquisition of a four-stranded helical structure
(quadruplex structure) by poly(G) and poly(I) has been sug-
gested as a crucial structural element for recognition by SCR
(36). Therefore, we surmised that oligonucleotides in contigu-
ity with poly(G) tails would be recognized by SCR if the innate
“tetraplex”-forming ability of the poly(G) carrier is not com-
promised. Although a poly(G) quartet (GGGG) is the mini-
mum stretch required for the acquisition of a quadruplex struc-
ture, the G tetramers may not assume this conformation due to
steric or other conformational constraints when placed in the
context of a relatively longer antisense sequence. Thus, it is
necessary to ascertain the optimum length of guanylic acid in
contiguity with the 15-mer antisense sequence that can take up
a tetraplex structure.
CD spectroscopy can be a useful tool for probing the pres-
ence of a tetraplex structure of deoxyguanylic acid oligomers
since the tetraplex structure exhibits a characteristic spectrum
(20, 22, 23, 29). In order to establish the minimum length of
guanylic acid tail for the poly(G) antisense oligonucleotide
constructs, we studied the CD spectra of the antisense con-
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structs in contiguity with a 4-mer, 7-mer, and 10-mer poly(G)
at the 39 end of the antisense sequence (Fig. 1). All three
spectra show two maxima and a minimum but at significantly
different wavelengths, suggesting the presence of differences in
the conformer populations. The two maxima for the 4-mer
construct are centered at 275 and 209 nm, while the minimum
is centered at 249 nm. The maximum at 275 nm and the
minimum at 249 nm of the 4-mer construct are blue shifted in
the 7-mer and 10-mer constructs. The spectra of the 10-mer
construct exhibit maxima near 261 and 209 nm and a minimum
near 241 nm. In addition there is a distinctive shoulder at 230
nm, which is absent in the spectra of lower oligomeric con-
structs. The spectra of the 10-mer construct are similar to the
previously described spectra of quadruplex-forming oligonu-
cleotides (20, 22, 23, 29) and are almost identical to the re-
ported spectra of a 6- or 12-mer deoxyguanylic acid (36). Thus,
the CD studies suggest that a 10-mer poly(G) stretch at the 39
end of the antisense sequence is able to maintain the tetraplex
structure just as in the isolated 6-mer or a 12-mer poly(G). We
therefore used 10-mer poly(G) tails at the 39 ends of the
oligonucleotides for their recognition by SCR present on mac-
rophages.
The 15-mer antisense oligonucleotide directed against the
translation initiation site of VSV was synthesized as a native
phosphodiester (ANS), as a PS (sANS), or as a chimeric mol-
ecule (cANS) where only the first and last internucleotide
linkages in the antisense portion of the oligonucleotide se-
quence were PS (Table 1). The 10-mer poly(G) tail at the 39
end of the oligonucleotide constructs was retained as PO to
facilitate degradation of the SCR recognition element
[poly(G) portion] on internalization. The antisense oligonucle-
otide was also synthesized with a 10-mer poly(C) tail at the 39
end (ANS-C) as a control sequence since poly(C) is not rec-
ognized by the SCR (11). Two other control oligonucleotides,
in which the 15-mer sequence complementary to ANS
(sense-G) and a scrambled sequence with the same composi-
tion as ANS (scram-G) were synthesized with poly(G) tails at
the 39 ends as shown in Table 1, were designed.
Recognition of oligonucleotide sequences by SCR. The spec-
ificity of recognition of the oligonucleotide-poly(G) constructs
by SCR was examined with J774E, a murine monocyte/macro-
phage cell line. For this purpose, first the status of SCR on
these cells was assessed. The binding of 125I-MBSA to J774E
cells at 4°C exhibited saturation kinetics with a half-maximal
binding of 2 mg/ml (data not shown). The degradation of 125I-
MBSA by J774E cells in the presence or absence of different
polyanionic molecules as competitors exhibited the character-
istic SCR profile; cells that received 2 mg of 125I-MBSA/ml
alone degraded 333 6 9.2 ng of 125I-MBSA/mg of cell protein
in 5 h. This value fell to 71 6 11 ng in the presence of unla-
beled MBSA (40 mg/ml), 90 6 8 ng in the presence of fucoidan
(20 mg/ml), and 33 6 5 ng in the presence of poly(G) (2 mg/ml).
Fetuin (20 mg/ml) and poly(C) (2 mg/ml) did not compete for
the degradation of 125I-MBSA. These results suggest the pres-
ence of normal SCR activity on J774E cells.
We investigated if the SCR on these cells recognized oligo-
nucleotides with 10-mer poly(G) tails at their 39 ends. To
establish this, the abilities of various oligonucleotides to com-
pete for the degradation of 125I-MBSA were tested. The 10-
mer poly(G) and oligonucleotides containing 10-mer poly(G)
tails at their 39 ends competed for the degradation of the
radiolabeled MBSA, while a 10-mer poly(C) and oligonucleo-
tides containing 10-mer poly(C) tails did not interfere with the
degradation of MBSA (Fig. 2). These results suggest that oli-
gonucleotides with poly(G) tails are efficiently recognized by
SCR. Furthermore, recognition of the poly(G) constructs by
the SCR was independent of both the sequence of the oligo-
nucleotides and chemical modifications to the backbone of the
oligonucleotides because Sense-G, Scram-G, cANS-G and
sANS-G competed for the degradation of 125I-MBSA as effi-
ciently as ANS-G itself.
Enhanced SCR-mediated uptake of oligonucleotides. Next
we examined the uptake of oligonucleotides with or without
poly(G) tails or containing poly(C) tails to assess the extent of
SCR-mediated facilitated delivery to the J774E cell line. The
data shown in Fig. 3A indicate that uptake of the oligonucle-
otide constructs with a poly(G) tail was 8- 12-fold higher than
uptake of constructs without the poly(G) extension. ANS-G,
cANS-G, sANS-G, and sense-G were taken up with compara-
ble efficiencies, whereas the uptake of ANS-C was around the
same level as that of ANS. This is consistent with the results of
the recognition studies described earlier in that poly(G)-con-
taining oligonucleotide sequences competed for the degrada-
tion of 125I-MBSA to similar extents while ANS and ANS-C
did not.
To further confirm that the enhanced uptake of the anti-
sense oligonucleotide containing a 10-mer poly(G) sequence
was mediated by SCR, the uptake of ANS-G by J774E cells was
competed by different polyanionic macromolecules. The re-
FIG. 1. CD spectra of poly(G) antisense oligonucleotides. The respective
oligonucleotides were dissolved in water at a nucleotide residue concentration of
about 60 mM, and the spectra were recorded with a 10-mm cell at 37°C. Each
spectrum represents an average of five scans. ANS with 4-mer poly(G) at the 39
end (– – – –), ANS with 7-mer poly(G) (— – —), and ANS with 10-mer poly(G)
(——) are shown.
TABLE 1. Oligonucleotide sequencesa
Oligomer Sequence
ANS ......................CAT TTT GAT TAC TGT
sANS.....................CAT TTT GAT TAC TGT
cANS.....................CAT TTT GAT TAC TGT
Sense .....................ACA GTA ATC AAA ATG
Scram ....................ATC GTA TTA CTT GTT
ANS-G..................CAT TTT GAT TAC TGT GGG GGG GGG G
sANS-G ................CAT TTT GAT TAC TGT GGG GGG GGG G
cANS-G ................CAT TTT GAT TAC TGT GGG GGG GGG G
Sense-G ................ACA GTA ATC AAA ATG GGG GGG GGG G
Scram-G................ATC GTA TTA CTT GTT GGG GGG GGG G
ANS-C ..................CAT TTT GAT TAC TGT CCC CCC CCC C
a The 15-mer antisense oligonucleotide (ANS) was directed against the trans-
lation initiation site of the VSV N protein mRNA. sANS, PS analog of ANS;
cANS, chimeric antisense oligomer with the first and last internucleotide linkages
modified by PS chemistry; sense, control sequence complementary to ANS;
scram, scrambled control sequence with the same composition as ANS; ANS-G,
sANS-G, cANS-G, sense-G, and scram-G are the respective oligonucleotides,
each containing a 10-mer poly(G) tail at the 39 end; ANS-C, control oligonucle-
otide sequence with ANS linked to a 10-mer poly(C) tail at the 39 end. The
internucleotide linkages for underlined sequences are linked through PS bonds.
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sults of this assay (Fig. 3B) showed that the uptake of ANS-G
was competed by known SCR ligands such as MBSA, fucoidan,
and poly(G). Fetuin and poly(C) did not show any effect. Thus
the observed enhanced uptake of the poly(G) constructs as
against that of the free oligonucleotides occurred predomi-
nantly through the SCR.
Bioefficacy of the poly(G)-containing oligonucleotides in
VSV-infected J774E cells. In order to test if the SCR-mediated
uptake led to enhanced bioefficacy, the ability of the antisense
oligonucleotide to inhibit VSV replication in SCR-bearing
J774E cells was investigated. VSV infected the J774E cell line,
and the virus was able to replicate in this cell line. The viral
titer generated 10 h postinfection, with a MOI of 0.5, was 15 3
106 PFU/ml. Cells were treated with increasing concentrations
of the ANS-G before being infected with VSV at a MOI of 0.5
as described in Materials and Methods. Under these condi-
tions significant inhibition of VSV replication was not observed
up to a concentration of 11 mM ANS-G. At 15 mM, the ANS-G
treatment brought about 80% inhibition of VSV replication
(Fig. 4). The cANS-G treatment yielded a similar profile of
FIG. 2. Recognition of poly(G) constructs by SCR; competition for degra-
dation of 125I-MBSA. Cells (0.5 3 106 cells/well) were plated in six-well culture
vessels and incubated for 18 h at 37°C. Each cell monolayer received 1 ml of
RPMI 1640 containing BSA (1 mg/ml) with 2 mg of 125I-MBSA (specific activity:
100 cpm/ng)/ml alone or along with different competitors and was incubated at
37°C. After 5 h of incubation, the medium in each well was processed to deter-
mine the amount of 125I-MBSA degraded, as described in Materials and Meth-
ods. The molar ratio of 125I-MBSA to different oligonucleotides was 1:20. Un-
labeled MBSA was used as a competitor at a concentration of 2 mg/ml. Both
poly(G) and poly(C) were 10-nucleotide-long molecules. Results shown are
means 6 standard errors of three independent determinations.
FIG. 3. Enhanced uptake of poly(G) constructs by J774E cells through the SCR. (A) Cells (0.5 3 106 cells/well) were plated in six-well culture vessels and were
incubated for 18 h at 37°C. Each cell monolayer received 1 ml of RPMI 1640 containing BSA (1 mg/ml), with 1 mM 32P-labeled oligonucleotide and was incubated at
37°C for the indicated periods of time. The cells were then processed as described in Materials and Methods, and cell-associated radioactivity was determined. Results
are means 6 standard errors of three independent determinations. (B) The assay was set up as described above. Cells received 1 mM 32P-labeled ANS-G (specific
activity: 555 cpm/pmol) either alone or along with different polyanionic macromolecules. The competitors used were MBSA (500 mg/ml), fetuin (100 mg/ml), fucoidan
(100 mg/ml), poly(G) (7 mg/ml), and poly(C) (7 mg/ml). After incubation for 4 h at 37°C, cell-associated radioactivity was determined. Uptake of ANS-G in the control
cells was 43.63 6 1.5 pmol/mg of cell protein. Results are expressed as means 6 standard errors of three independent determinations.
FIG. 4. Dose dependence of ANS-G on inhibition of VSV replication. Cells
(0.125 3 106 cells/well) were treated with various concentrations of ANS-G in
250 ml of serum-free RPMI 1640 for 4 h at 37°C. The cells were then infected
with VSV at a MOI of 0.5 for 30 min after which they were given three rapid
washes. The cells were incubated at 37°C for 10 h postinfection in medium
containing the oligonucleotides with 2% FBS. Culture supernatants were col-
lected, and viral titers were estimated by plaque assays of CHO cell monolayers.
Results shown are means 6 standard errors of three independent determina-
tions.
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inhibition of VSV replication. The antisense effects due to
ANS-G and cANS-G were not further enhanced when the
concentration was increased to 30 mM. In contrast, the free
antisense oligonucleotide (ANS), under assay conditions sim-
ilar to those employed for the ANS-G treatment, did not sig-
nificantly inhibit the VSV replication up to a concentration of
30 mM. Representative data in Fig. 5A show that the control
oligonucleotides, sense-G, scram-G, and ANS-C, exhibited be-
havior similar to that of ANS. The carrier molecule [10-mer
poly(G)] itself did not interfere with the viral replication.
To establish that the observed inhibition of VSV replication
was a result of SCR-mediated delivery, cells were incubated
with the ANS-G conjugate in the presence or absence of poly-
anionic macromolecules known to be ligands of the SCR or
otherwise. The coincubation with poly(G), an SCR ligand,
resulted in complete abrogation of the antisense effect,
whereas poly(C), which is not recognized by the SCR, caused
no significant reversal of the antisense-mediated effect (Fig.
5B).
Bioefficacy in CHO transfectants. One of the enduring prob-
lems faced in antisense research has been the variability of
antisense effects in different cell lines against the same target.
Therefore, it was pertinent to examine the bioefficacy of the
SCR-mediated delivery of antisense oligonucleotides in other
SCR-bearing cell lines. CHO cells that were stably transfected
with the SCR type I (PJA28.C5 cells) were chosen for this
purpose. The PJA28.C5 cells bound 125I-MBSA at 4°C with
saturation kinetics (data not shown). Also, degradation of 125I-
MBSA by these cells (64 6 1.47 ng/mg of cell protein in 5 h)
was effectively competed by MBSA and poly(G) but not by
poly(C) or fetuin, indicating expression of characteristic SCR
activity. However, in comparison to that for the J774E cell line,
the level of degradation of 125I-MBSA in PJA28.C5 was about
four- to fivefold lower.
The levels of uptake of ANS and ANS-G were similar in the
parental CHO cells that did not express SCR. In contrast,
SCR-transfected PJA28C.5 cells took up the ANS-G oligonu-
cleotide about 8- to 10-fold more efficiently than ANS (Fig.
6A). This amount of enhancement of uptake of ANS-G by
PJA28C.5 cells was similar to that observed for J774E cells.
However, the absolute amount of oligonucleotide taken up by
the PJA28.C5 cells was about twofold less than the uptake by
J774E cells. These results are consistent with the lower SCR
activity in the CHO transfectants. The enhanced uptake of the
poly(G) conjugate occurred predominantly through the SCR,
as demonstrated in the results shown in Fig. 6B. The uptake
was competed by known SCR ligands such as MBSA, poly(G),
and fucoidan but was not affected by other polyanionic mac-
romolecules such as poly(C) and fetuin, which are not recog-
nized by the SCR.
VSV infected and replicated in PJA28.C5 cells. At a MOI of
0.5, 10 h postinfection, a viral titer of 37 3 106 was generated.
VSV was therefore able to replicate more efficiently in the
CHO transfectant than in the J774E cell line where only 15 3
106 PFU/ml was generated under identical conditions of infec-
tion. Treatment with ANS-G at a concentration of 15 mM
caused 65% inhibition of VSV replication (Fig. 7), whereas
ANS, sense-G, and ANS-C, at the same concentration, did not
cause inhibition of VSV replication. However, 10-mer poly(G)
elicited a small antiviral activity. This is in contrast to the
bioefficacy results for J774E-infected cells, where poly(G) was
completely ineffective.
DISCUSSION
The poor cellular uptake of oligonucleotides remains a ma-
jor stumbling block in the development of antisense therapy.
Although the problem has been circumvented to some extent
by utilizing cationic and other lipids (27, 42) and certain re-
ceptor systems (15, 49, 50), most of these delivery systems are
complicated by multistep preparation procedures yielding
poorly defined heterogeneous mixtures. Here we report a sim-
ple approach to augment the antisense oligonucleotide uptake
in macrophages that express SCR. We have exploited the in-
nate tetraplex-forming propensity of poly(G) sequences and
the ability of SCR to recognize this feature of the poly(G)
conformation for targeting antisense oligonucleotides to mac-
rophages. We show that oligonucleotides containing 10-mer
poly(G) stretches at the 39 termini are recognized and effi-
ciently taken up by SCR and that this receptor-mediated up-
take of antisense oligonucleotides directed against the N pro-
tein mRNA of VSV leads to inhibition of VSV replication in
FIG. 5. Inhibition of VSV replication in J774E cells by different oligonucleotide constructs. (A) Cells (0.125 3 106 cells/well) were treated with 15 mM
concentrations of oligonucleotides, and assays were carried out as described in the legend for Fig. 4. Results shown are means 6 standard errors of three independent
determinations. (B) Reversal of antisense effects by competing polyanionic macromolecules. The assay was performed as described above. Cells received, in addition
to ANS-G, 7 mg of either poly(G) or poly(C) as competitors. The viral titer in the control group was 16 3 106 PFU/ml. Results shown are means 6 standard errors
of three independent determinations.
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J774E macrophage cells as well as in CHO cells transfected
with SCR.
In designing the poly(G)-antisense oligonucleotide con-
structs for SCR-mediated targeted delivery to cells, the nucle-
ase sensitivity of antisense molecules was kept in mind. Thus
antisense molecules using PS chemistry (sANS) were synthe-
sized. However, in standard trypan blue exclusion studies,
sANS was found to be extremely toxic to cells at concentrations
of 15 mM; nearly 90 to 95% of the cells became permeable to
the dye after incubation with sANS for 5 h at 37°C. However,
chimeric molecules (cANS) in which only the first and last
internucleotide linkages were modified by PS chemistry were
not toxic to cells at concentrations as high as 100 mM.
Nonetheless, the poly(G) constructs of PO oligonucleotides
(ANS-G) were as bioeffective as chimeric oligonucleotides
(cANS-G). The ability of ANS-G to inhibit VSV replication
with efficiency almost identical to that of the cANS-G is an
interesting result that suggests longer intracellular survival of
the poly(G)-tethered antisense oligonucleotides. The reasons
for the enhancement in the stability of oligonucleotides deliv-
ered through the SCR pathway are not readily apparent. The
trafficking into specific intracellular compartments, which en-
sures a longer half-life of the antisense molecules, may be one
of the reasons. It is also likely that the quadruplex structures
acquired by the poly(G) tail may offer resistance to degrada-
tion and increase the half-life of the molecule. If this be so,
then the fact that we have used antisense oligonucleotides with
poly(G) tails at the 39 ends may be important because the
degradation of oligonucleotides is believed to occur predomi-
nantly due to 39-exonuclease activity (37). It would also mean
that using poly(G) as a carrier for PO antisense oligonucleo-
tides may increase their stability due to the intrinsic properties
of the carrier molecule. These results are important in the light
of several recent reports questioning the use of PS oligonucle-
otides (43), which are now known to have serious drawbacks
which include non-sequence-specific effects (37, 38), inhibition
of important cellular enzymes such as human DNA poly-
merases and RNase H (16), and binding to several cytosolic
proteins leading to cellular toxicity (10, 21).
The optimum concentration (15 mM) required to achieve
80% inhibition of VSV replication in J774E-infected cells com-
pares favorably with the previously published data. Agris et al.
(3) used methylphosphonate oligonucleotides at 150 mM for
inhibiting VSV replication in L929 cells, while 50 mM was
required for in vitro specific inhibition of hepatitis B viral gene
expression by asialoglycoprotein-mediated delivery of anti-
sense compounds to virus-infected HepG2 cells that possess
the asialoglycoprotein receptors (50). Thus the results of the
present study are significant in the light of the above observa-
tions. However, oligonucleotides are known to effect the inhi-
bition of replication of certain viruses even at nanomolar con-
centrations. The use of a relatively higher oligonucleotide
concentration for VSV in the present study may be related to
the intrinsic high growth rate of this virus. In a recent study,
Tackas and Banerjee (45) could demonstrate the inhibition of
VSV in cells constitutively expressing an antisense RNA tar-
geted against the virus L protein gene only at a very low MOI
of 0.01 to 0.1 and concluded that the “robust growth rate of
VSV eventually overwhelms the available antisense RNA and
leads to delayed cell death.”
FIG. 6. Enhanced uptake of ANS-G by parent CHO cells and PJA28.C5 cells expressing SCR. (A) The assay was performed as described for Fig. 3A. Results shown
are means 6 standard errors for three independent determinations. ODN, oligonucleotide. (B) Assay was carried out as described for Fig. 3B. Cells received 1 mM
32P-labeled ANS-G (specific activity: 390 cpm/pmol) either alone or along with different competitors, viz., MBSA (500 mg/ml), poly(G) (7 mg/ml), fucoidan (100 mg/ml),
poly(C) (7 mg/ml), and fetuin (100 mg/ml). Results shown are means 6 standard errors of three independent determinations.
FIG. 7. Inhibition of VSV replication in PJA28.C5 cells treated with ANS-G.
The experiment was performed as described for Fig. 4. All oligonucleotides were
used at a concentration of 15 mM. Results shown are means 6 standard errors
of three independent determinations.
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MBSA, a ligand of the SCR, has been used to target a variety
of chemotherapeutic agents (14, 30–34) to macrophage cells.
Chaudhury (14) has used liposome coated with MBSA to de-
liver antisense oligonucleotides to macrophage cells. We have
also noted SCR-mediated enhanced uptake of oligonucleo-
tides conjugated to MBSA by macrophages (data not shown).
However, the immunogenicity of maleylated proteins (1) and
the multistep, complex procedure for preparation of conju-
gates of an antisense oligonucleotide with the maleylated pro-
tein complicate its utility as a carrier of oligonucleotides to
macrophages. In contrast, poly(G) molecules are not likely to
induce an immune response and using poly(G) as a carrier
eliminates the need for complex conjugation procedures be-
cause the addition of a poly(G) tail to the antisense sequence
is very much a part of the solid-phase synthesis of oligonucle-
otides. However, there have been reports suggesting that the
presence of G tetrads comprising both PS and PO oligonucle-
otides does cause sequence-independent effects (43); some
examples include inhibition of human immunodeficiency virus
(35, 46) and the biological activity of RelA (7) and c-myb (12).
Binding of G tetrads to fibroblast growth factor has also been
reported (21). Nonetheless, we did not observe any effect of
10-mer poly(G) on cell proliferation and viability up to con-
centrations of 100 mM. Poly(G) also did not elicit antiviral
activity in VSV-infected J774E cells. However, VSV replica-
tion was marginally inhibited in CHO transfectants, suggesting
that the antiviral activity of poly(G) might be intrinsic to the
nature of the cell lines.
In some recent studies, SCR has been suggested to mediate
oligonucleotide binding. SCR present on endothelial liver cells
are implicated in liver uptake of oligonucleotides (8). Also
Kimura et al. (24) reported the blockage of oligomer induction
of interferon production on NK cells by ligands of SCR and
suggested that SCR bound to oligonucleotides. However, these
results are not in agreement with the findings of Benimetskaya
et al. (7), who showed that binding of oligonucleotides to
macrophages and microglia cells was unaffected by ligands of
the SCR. The findings of Benimetskaya et al. are consistent
with our results in that only those oligonucleotides that are
compatible with the SCR ligand specificity are recognized.
Furthermore, SCR recognition of poly(G) constructs and
bioefficacy are consistent with the results of Chaudhury (14),
who showed enhanced efficacy of SCR-mediated delivery of
antileishmanial oligonucleotides encapsulated in MBSA-
coated liposome.
Macrophages are an important component of the cellular
arm of the immune system and are infected by many viral
pathogens including human immunodeficiency virus and den-
gue virus. The idea of targeting oligonucleotides specifically to
macrophages is, therefore, of considerable therapeutic signif-
icance. The SCR system lends itself admirably to this purpose,
as the SCR receptors are predominantly expressed on cells of
the macrophage lineage. Further, the levels of expression are
high and the receptors are not down regulated on association
with ligands and are recycled rapidly back to the surface after
internalization (4). The SCR system has been used extensively
for the targeted delivery of a variety of chemotherapeutic
agents to macrophages to eliminate intracellular infectious
agents as well as certain forms of cancer involving macrophage
lineage cells both in vitro and in vivo (30–34). The present
studies describing a simple strategy of SCR-mediated targeting
of antisense oligonucleotides to macrophages is likely to facil-
itate the antisense-mediated therapy of macrophage-related
intracellular infections of viral, bacterial, or protozoal etiology
and would also serve as a facile way for modulating or con-
trolling certain metabolic responses of macrophages that might
have therapeutic implications. Furthermore, it would be of
interest to explore if poly(G)-mediated targeting could be
adapted for delivery of genes to SCR-bearing cells.
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